Victory Capital Management Inc. Sells 101,377 Shares of Eli Lilly and Company (NYSE:LLY)

Victory Capital Management Inc. decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 13.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 659,585 shares of the company’s stock after selling 101,377 shares during the period. Victory Capital Management Inc.’s holdings in Eli Lilly and Company were worth $384,485,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Lipe & Dalton purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $26,000. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter valued at approximately $35,000. Optiver Holding B.V. bought a new stake in Eli Lilly and Company during the third quarter worth $36,000. Finally, Family CFO Inc purchased a new position in Eli Lilly and Company in the third quarter worth $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on LLY. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. BMO Capital Markets raised their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday. Citigroup upped their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $742.95.

Eli Lilly and Company Stock Down 0.9 %

LLY traded down $6.86 during trading on Wednesday, hitting $774.24. 1,254,453 shares of the company’s stock traded hands, compared to its average volume of 3,048,152. The stock has a market capitalization of $735.65 billion, a price-to-earnings ratio of 133.47, a PEG ratio of 1.61 and a beta of 0.34. The company’s 50 day simple moving average is $761.41 and its two-hundred day simple moving average is $669.21. Eli Lilly and Company has a 12-month low of $399.26 and a 12-month high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the previous year, the company earned $1.62 earnings per share. The firm’s quarterly revenue was up 26.0% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.